Unlocking biological complexity to transform pharma R&D

Opening the door to synergistic therapies

Insights

Simultaneous modulation of multiple biological pathways vastly improves therapeutic potential.

Decades of prior investment in biology, genetics, and approved drugs enables us to harness biological complexity and address major medical needs in the clinic now.

Technology

Our Locksmith® platform uses AI-enhanced computational genetics to identify pairs of biological pathways that act synergistically in disease, making them ideal targets for therapeutic intervention.

Results

Locksmith opens the door to a new class of synergistic therapies that target pathway pairs, including:
• novel drug combinations — including drugs developed for other indications
• novel multifunctional drugs

Who we are

We are biotech and pharma veterans with diverse backgrounds in computational and experimental drug discovery and a shared dedication to improving the lives of patients with complex diseases.

Bruce Beutel

Founder, CEO

Will Chen

Co-Founder, Chief Technology Officer

Passkey Therapeutics Launches with Platform to Design Multifunctional Drugs

Bruce Beutel, PhD, who has worked in the drug development industry for over thirty years is ready for a change. He wants to move beyond the single target paradigm, in...

Passkey Therapeutics launches with $20M to focus on pipeline, partnerships

After establishing its platform, Passkey Therapeutics Inc. is now emerging from stealth to focus on building its pipeline and partnerships...

Passkey aims to use single drugs for multiple proteins

A trio of biotech and pharma executives with backgrounds in computational chemistry and systems biology are making a bet: that new computational tools will allow them to go after multiple...

Passkey Therapeutics Raises $20 Million to Advance a New Class of Multifunctional Therapeutics with Proprietary Platform Targeting Rare Combinations of Proteins

Cambridge, MA, October 22, 2024 — Passkey Therapeutics, the pioneer of Synergistic Multifunctional Therapeutics (SMThs), announced today that it has emerged from stealth with $20 million in seed funding led...